



GUOPEI LUO, PhD, MD

Shanghai Cancer Center, Shanghai, China

EDUCATION

Joint-trained Ph.D. student, from 2008 to 2009, University of California, Irvine

Ph.D. student specialized in pancreatic cancer, from 2005 to 2010, Fudan University of Shanghai, China

MD, Clinical Medicine, bachelor's degree, from 2000 to 2005, Gannan Medical University, Jiangxi Province, China

CURRENT POSITIONS

October 2016 – Associate Professor, Department of Pancreatic Surgery, Shanghai Cancer center

PREVIOUS POSITIONS HELD

July 2010 – July 2012, Resident Physician, Department of Pancreatic Surgery, Shanghai Cancer center

Aug 2012 – September 2016, Attending Physician, Department of Pancreatic Surgery, Shanghai Cancer center

ACADEMIC RECOGNITION

2011 - Young Investigator Travel Award, American Pancreatic Association

2008 - Excellent Award in the National Medical Graduate Annual Meeting

2005 - National Top-grade MD Student Scholarship of China

RESEARCH

Since the commencement of my PhD, I have dedicated my career to the research of pancreatic cancer.

PhD Program: Special drug delivery system for pancreatic cancer, using biodegradable high molecular materials including Albumin, PLGA, and Poloxamer, directing by a special target called LyP-1 peptide.

Post PhD training: Translational research in pancreatic cancer, including 1) Molecular and clinicopathological features of CA19-9 low-expression pancreatic cancer; 2) Translational research about pancreatic cancer and pancreatic neuroendocrine tumour.

GRANT FUNDING RECEIVED

2010 Yong investigator starting program of Fudan University

2010 Yong investigator promoting program of Fudan University

2011 National Natural Science Foundation of China (NSFC)

2014 Rising star program, Natural Science Foundation of Shanghai

2016 Shanghai Natural Science Foundation

APPOINTMENTS/SCIENTIFIC COMMITTEES

2014 - ongoing Editorial Board Member – Oncology Letters

2012 - ongoing Secretary, Pancreatic Cancer Committee of Chinese Anti-Cancer Association (PCCA)

2011- ongoing Member, American Pancreatic Association (APA)

2014- ongoing Member, International Association of Pancreatology (IAP)

PUBLICATIONS

- [1] Zhang Y, Yang C, Cheng H, Fan Z, Huang Q, Lu Y, Fan K, **Luo G**, Jin K, Wang Z, Liu C, Yu X. Novel agents for pancreatic ductal adenocarcinoma: emerging therapeutics and future directions. *J Hematol Oncol.* 2018;11(1):14.
- [2] Fan K, Yang C, Fan Z, Huang Q, Zhang Y, Cheng H, Jin K, Lu Y, Wang Z, **Luo G**, Yu X, Liu C. MUC16 C terminal-induced secretion of tumor-derived IL-6 contributes to tumor-associated Treg enrichment in pancreatic cancer. *Cancer Lett.* 2018;418:167-175.
- [3] **Luo G**, Jin K, Cheng H, Liu C, Guo M, Lu Y, Yang C, Xu J, Wang W, Gao H, Zhang S, Long J, Xu J, Ni Q, Chen J, Yu X. Carbohydrate antigen 19-9 as a prognostic biomarker in pancreatic neuroendocrine tumors. *Oncol Lett.* 2017;14(6):6795-6800.
- [4] Guo M, **Luo G**, Lu R, Shi W, Cheng H, Lu Y, Jin K, Yang C, Wang Z, Long J, Xu J, Ni Q, Liu C, Yu X. Distribution of Lewis and Secretor polymorphisms and corresponding CA19-9 antigen expression in a Chinese population. *FEBS Open Bio.* 2017;7(11):1660-1671.
- [5] **Luo G**, Javed A, Strosberg JR, Jin K, Zhang Y, Liu C, Xu J, Soares K, Weiss MJ, Zheng L, Wolfgang CL, Cives M, Wong J, Wang W, Sun J, Shao C, Wang W, Tan H, Li J, Ni Q, Shen L, Chen M, He J, Chen J, Yu X. Modified Staging Classification for Pancreatic Neuroendocrine Tumors on the Basis of the American Joint Committee on Cancer and European Neuroendocrine Tumor Society Systems. *J Clin Oncol.* 2017;35(3):274-280.
- [6] **Luo G**, Liu C, Guo M, Long J, Liu Z, Xiao Z, Jin K, Cheng H, Lu Y, Ni Q, Yu X. CA19-9-Low&Lewis (+) pancreatic cancer: a unique subtype. *Cancer Lett.* 2017;385:46-50.
- [7] **Luo G**, Liu C, Guo M, Cheng H, Lu Y, Jin K, Liu L, Long J, Xu J, Lu R, Ni Q, Yu X. Potential Biomarkers in Lewis Negative Patients With Pancreatic Cancer. *Ann Surg.* 2017;265(4):800-805.
- [8] Liu C, Cheng H, **Luo G**, Lu Y, Jin K, Guo M, Ni Q, Yu X. Circulating regulatory T cell subsets predict overall survival of patients with unresectable pancreatic cancer. *Int J Oncol.* 2017;51(2):686-694.
- [9] **Luo G**, Jin K, Cheng H, Guo M, Lu Y, Wang Z, Yang C, Xu J, Gao H, Zhang S, Zhang B, Long J, Xu J, Ni Q, Liu C, Yu X. Revised nodal stage for pancreatic neuroendocrine tumors. *Pancreatology.* 2017;17(4):599-604.
- [10] Jin K, **Luo G**, Xu J, Zhang B, Liu C, Ji S, Liu L, Long J, Ni Q, Yu X. Clinical outcomes and prognostic factors of resected pancreatic neuroendocrine neoplasms: A single-center experience in China. *Oncol Lett.* 2017;13(5):3163-3168.
- [11] **Luo G**, Liu C, Cheng H, Jin K, Guo M, Lu Y, Long J, Xu J, Ni Q, Chen J, Yu X. Neutrophil-lymphocyte ratio predicts survival in pancreatic neuroendocrine

- tumors. *Oncol Lett.* 2017;13(4):2454-2458.
- [12] Cheng H, Liu C, Jiang J, **Luo G**, Lu Y, Jin K, Guo M, Zhang Z, Xu J, Liu L, Ni Q, Yu X. Analysis of ctDNA to predict prognosis and monitor treatment responses in metastatic pancreatic cancer patients. *Int J Cancer.* 2017;140(10):2344-2350.
- [13] Guo M, **Luo G**, Jin K, Long J, Cheng H, Lu Y, Wang Z, Yang C, Xu J, Ni Q, Yu X, Liu C. Somatic Genetic Variation in Solid Pseudopapillary Tumor of the Pancreas by Whole Exome Sequencing. *Int J Mol Sci.* 2017;18(1).
- [14] **Luo G**, Jin K, Guo M, Cheng H, Liu Z, Xiao Z, Lu Y, Long J, Liu L, Xu J, Liu C, Gao Y, Ni Q, Yu X. Patients with normal-range CA19-9 levels represent a distinct subgroup of pancreatic cancer patients. *Oncol Lett.* 2017;13(2):881-886.
- [15] Liu Z, Jin K, Guo M, Long J, Liu L, Liu C, Xu J, Ni Q, **Luo G**, Yu X. Prognostic Value of the CRP/Alb Ratio, a Novel Inflammation-Based Score in Pancreatic Cancer. *Ann Surg Oncol.* 2017;24(2):561-568.
- [16] Liang C, Qin Y, Zhang B, Ji S, Shi S, Xu W, Liu J, Xiang J, Liang D, Hu Q, Liu L, Liu C, **Luo G**, Ni Q, Xu J, Yu X. Energy sources identify metabolic phenotypes in pancreatic cancer. *Acta Biochim Biophys Sin (Shanghai).* 2016;48(11):969-979.
- [17] **Luo G**, Guo M, Jin K, Liu Z, Liu C, Cheng H, Lu Y, Long J, Liu L, Xu J, Ni Q, Yu X. Optimize CA19-9 in detecting pancreatic cancer by Lewis and Secretor genotyping. *Pancreatology.* 2016;16(6):1057-1062.
- [18] Cheng H, **Luo G**, Lu Y, Jin K, Guo M, Xu J, Long J, Liu L, Yu X, Liu C. The combination of systemic inflammation-based marker NLR and circulating regulatory T cells predicts the prognosis of resectable pancreatic cancer patients. *Pancreatology.* 2016;16(6):1080-1084.
- [19] Guo M, **Luo G**, Liu C, Cheng H, Lu Y, Jin K, Liu Z, Long J, Liu L, Xu J, Huang D, Ni Q, Yu X. The Prognostic and Predictive Role of Epidermal Growth Factor Receptor in Surgical Resected Pancreatic Cancer. *Int. J. Mol. Sci.* 2016, 17(7), 1090.
- [20] Liu C, Lu Y, **Luo G**, Cheng H, Guo M, Liu Z, Xu J, Long J, Liu L, Fu D, Ni Q, Li M, Yu X. Which patients with para-aortic lymph node (LN16) metastasis will truly benefit from curative pancreaticoduodenectomy for pancreatic head cancer? *Oncotarget.* 2016;7(20):29177-86.
- [21] Xiao Z, **Luo G**, Liu Z, Jin K, Xu J, Liu C, Liu L, Ni Q, Long J, Yu X. Roux-en-Y pancreaticojejunostomy reconstruction after deep enucleation of benign or borderline pancreatic lesions: a single-institution experience. *HPB (Oxford).* 2016,18(2):145-152.
- [22] **Luo G**, Guo M, Liu Z, Xiao Z, Jin K, Long J, Liu L, Liu C, Xu J, Ni Q, Yu X. Blood neutrophil-lymphocyte ratio predicts survival in patients with advanced pancreatic cancer treated with chemotherapy. *Ann Surg Oncol.* 2015;22(2):670-6.
- [23] **Luo G**, Liu Z, Guo M, Jin K, Xiao Z, Liu L, Liu C, Xu J, Ni Q, Long J, Yu X. A comprehensive comparison of clinicopathologic and imaging features of

- incidental/symptomatic non-functioning pancreatic neuroendocrine tumors: A retrospective study of a single center. *Pancreatology*. 2015,15(5):519-524.
- [24] Jin K, **Luo G**, Xiao Z, Liu Z, Liu C, Ji S, Xu J, Liu L, Long J, Ni Q, Yu X. Noncoding RNAs as potential biomarkers to predict the outcome in pancreatic cancer. *Drug Des Devel Ther*. 2015,9:1247-1255.
- [25] **Luo G**, Lu Y, Jin K, Cheng H, Guo M, Liu Z, Long J, Liu C, Ni Q, Yu X. Pancreatic cancer: BRCA mutation and personalized treatment. *Expert Rev Anticancer Ther*. 2015,15(10):1223-1231.
- [26] Liu Z, **Luo G**, Guo M, Jin K, Xiao Z, Liu L, Liu C, Xu J, Ni Q, Long J, Yu X. Lymph node status predicts the benefit of adjuvant chemoradiotherapy for patients with resected pancreatic cancer. *Pancreatology*. 2015,15(3):253-258.
- [27] Liu ZQ, Xiao ZW, **Luo GP**, Liu L, Liu C, Xu J, Long J, Ni QX, Yu XJ. Effect of the number of positive lymph nodes and lymph node ratio on prognosis of patients after resection of pancreatic adenocarcinoma. *Hepatobiliary Pancreat Dis Int*. 2014;13(6):634-41.
- [28] **Luo G**, Liu Z, Guo M, Jin K, Xiao Z, Liu L, Xu J, Zhang B, Liu C, Huang D, Hu S, Ni Q, Long J, Yu X. F-18-FDG PET/CT can be used to detect non-functioning pancreatic neuroendocrine tumors. *International Journal of Oncology*. 2014,45(4):1531-1536.
- [29] Long J, **Luo GP**, Xiao ZW, Liu ZQ, Guo M, Liu L, Liu C, Xu J, Gao YT, Zheng Y, Wu C, Ni QX, Li M, Yu X. Cancer statistics: Current diagnosis and treatment of pancreatic cancer in Shanghai, China. *Cancer Letters*. 2014,346(2):273-277.
- [30] Xiao Z, **Luo G**, Liu C, Wu C, Liu L, Liu Z, Ni Q, Long J, Yu X. Molecular Mechanism Underlying Lymphatic Metastasis in Pancreatic Cancer. *Biomed Research International*. 2014,925845:1-15.
- [31] **Luo G**, Xiao Z, Long J, Liu Z, Liu L, Liu C, Xu J, Ni Q, Yu X. CA125 is Superior to CA19 - 9 in Predicting the Resectability of Pancreatic Cancer. *Journal of Gastrointestinal Surgery*. 2013,12:2092-2098.
- [32] Wang WQ, Liu L, Xu HX, **Luo GP**, Chen T, Wu CT, Xu YF, Xu J, Liu C, Zhang B, Long J, Tang ZY, Yu XJ. Intratumoral α -SMA enhances the prognostic potency of CD34 associated with maintenance of microvessel integrity in hepatocellular carcinoma and pancreatic cancer. *PLoS One*. 2013;8(8):e71189.
- [33] **Luo G**, Long J, Cui X, Xiao Z, Liu Z, Shi S, Liu L, Liu C, Xu J, Li M, Yu X. Highly lymphatic metastatic pancreatic cancer cells possess stem cell-like properties. *International Journal of Oncology*. 2013, 42(3):979-984.
- [34] Zhang B, Xu J, Liu C, Long J, Liu L, Xu Y, Wu C, **Luo G**, Ni Q, Li M, Yu X. Application of "papillary-like main pancreatic duct invaginated" pancreaticojejunostomy for normal soft pancreas cases. *Sci Rep*. 2013;3:2068. doi: 10.1038/srep02068.
- [35] **Luo G**, Long J, Zhang B, Liu C, Xu J, Ni Q, Yu X. Stroma and pancreatic ductal adenocarcinoma: An interaction loop, *Biochimica et Biophysica Acta-Reviews on Cancer*. 2012,1826(1):170-178.

- [36] **Luo G**, Long J, Zhang B, Liu C, Ji S, Xu J, Yu X, Ni Q. Quantum dots in cancer therapy. *Expert Opinion on Drug Delivery*. 2012,9(1):47-58.
- [37] Long J, **Luo G**, Liu C, Cui X, Satoh K, Xiao Z, Zhang B, Xu J, Ni Q, Li M, Yu X. Development of a unique mouse model for pancreatic cancer lymphatic metastasis , *International Journal of Oncology*. 2012,41(5):1662-1668.
- [38] Li J, **Luo G**, Fu D, Jin C, Hao S, Yang F, Wang X, Yao L, Ni Q. Preoperative diagnosis of nonfunctioning pancreatic neuroendocrine tumors , *Medical Oncology*. 2011,28(4):1027-1031.
- [39] **Luo G**, Long J, Qiu L, Liu C, Xu J, Yu X. Role of Epidermal Growth Factor Receptor Expression on Patient Survival in Pancreatic Cancer: A Meta-Analysis. *Pancreatology*. 2011,11(6):595-600.
- [40] **Luo G**, Long J, Zhang B, Liu C, Xu J, Yu X, Ni Q. Developmental plasticity of stem cells and diseases. *Medical Hypotheses*. 2010,75(6):507-510.
- [41] **Luo G**, Yu X, Jin C, Yang F, Fu D, Long J, Xu J, Zhan C, Lu W. LyP-1-conjugated nanoparticles for targeting drug delivery to lymphatic metastatic tumors , *International Journal of Pharmaceutics*. 2010,385(1-2):150-156.
- [42] Xu J, Jin C, Hao S, **Luo G**, Fu D. Pancreatic cancer: gene therapy approaches and gene delivery systems. *Expert Opin Biol Ther*. 2010;10(1):73-88.
- [43] **Luo G**, Jin C, Fu D, Long J, Yang F, Ni Q. Primary pancreatic lymphoma. *Tumori*. 2009,95(2):156-159.
- [44] **Luo G**, Jin C, Long J, Fu D, Yang F, Xu J, Yu X, Chen W, Ni Q. RNA interference of MBD1 in BxPC-3 human pancreatic cancer cells delivered by PLGA-poloxamer nanoparticles. *Cancer Biol Ther*. 2009,8(7):594-598.
- [45] Yang F, Hu J, Yang D, Long J, **Luo G**, Jin C, Yu X, Xu J, Wang C, Ni Q, Fu D. Pilot study of targeting magnetic carbon nanotubes to lymph nodes. *Nanomedicine (Lond)*. 2009 ;4(3):317-30.